CA2501818A1 - Pharmaceutical compositions directed to erb-b1 receptors - Google Patents

Pharmaceutical compositions directed to erb-b1 receptors Download PDF

Info

Publication number
CA2501818A1
CA2501818A1 CA002501818A CA2501818A CA2501818A1 CA 2501818 A1 CA2501818 A1 CA 2501818A1 CA 002501818 A CA002501818 A CA 002501818A CA 2501818 A CA2501818 A CA 2501818A CA 2501818 A1 CA2501818 A1 CA 2501818A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
receptor
antibody
erbb1
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002501818A
Other languages
French (fr)
Other versions
CA2501818C (en
Inventor
Hans-Georg Kreysch
Juergen Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2501818A1 publication Critical patent/CA2501818A1/en
Application granted granted Critical
Publication of CA2501818C publication Critical patent/CA2501818C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Abstract

The invention relates to pharmaceutical compositions comprising different molecules, preferably monoclonal antibodies, each comprising epitopes that bind simultaneously to different sites within the same ErbB 1 receptor domain.
The preferred antibodies according to this invention are MAb 425 and MAb 225 each in its murine, chimeric and humanized version. The invention relates to the use and methods for an improved treatment of preferably tumors by means of said compositions.

Claims (29)

Claims:
1. A pharmaceutical composition comprising a first and a second antibody molecule, or a portion thereof, having the capability to bind to different epitopes located on same or different ErbB receptor molecule types, wherein said first antibody molecule or a portion thereof, comprises binding sites that bind to a first specific epitope on the ErbB1 receptor molecule type, and said second antibody molecule comprises binding sites that bind to a second specific epitope on the same ErbB1 receptor molecule type.
2. A pharmaceutical composition according to claim 1 or 2, wherein at least said first or said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
3. A pharmaceutical composition according to claim 1, wherein said first and said second epitope on the ErbB1 receptor molecule type is located within the ErbB1 receptor binding domain.
4. A pharmaceutical composition according to claim 2 or 3, wherein said receptor binding domain is the binding domain of the natural ligand of said ErbB1 receptor molecule type.
5. A pharmaceutical composition according to claim 2 or 3, wherein the first and second antibody, or fragment thereof, binds to different epitopes within the binding domain of the natural ligand(s) of said ErbB1 receptor molecule type.
6. A pharmaceutical composition according claims 5, wherein blocking and / or inhibition of the ErbB receptor, and induction of down-regulation of ErbB
receptor-specific pathway signaling is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.
7. A pharmaceutical composition according to any of the claims 1 to 6, wherein the induction of cross-linking and / or dimerization of ErbB receptor molecules of the same or different specificity is enhanced as compared with a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule type only.
8. A pharmaceutical composition of claim 7, wherein said ErbB receptor molecules, are involved in cross-linking and / or dimerization, and are selected from ErbB1 and ErbB2 (Her-2).
9. A pharmaceutical composition according to any of the claims 1- 8, wherein said first and / or said second antibodies is a monospecific antibody.
10. A pharmaceutical composition according to any of the claims 1 to 9, wherein the first antibody is murine, chimeric or humanized MAb 425.
11. A pharmaceutical composition according to any of the claims 1 to 9, wherein the second antibody is murine, chimeric or humanized MAb 225.
12. A pharmaceutical composition according to claim 10 or 11, wherein said first antibody is humanized MAb 425 (h425) and said second antibody is chimeric MAb 225 (c225).
13. A pharmaceutical composition according to any of the claims 1 to 12, comprising additionally a cytotoxic agent.
4. A pharmaceutical composition according to claim 13, wherein said cytotoxic agent is a chemotherapeutic agent.
15. A pharmaceutical composition according of claim 14, wherein said chemotherapeutic agent is selected from any of the compounds of the group:
cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.
16. A pharmaceutical composition of claim 15, wherein said cytotoxic agent is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.
17. A pharmaceutical composition according to any of the claims 1 to 12, wherein said first and / or said second antibody molecule is an immunoconjugate, wherein the antibody portion is fused by its C-terminus to a biologically effective peptide, polypeptide or protein, optionally via a linker peptide.
18. A pharmaceutical composition of claim 17, wherein the protein is a cytokine.
19. A pharmaceutical kit comprising (i) a first package comprising a first antibody molecule, or a portion thereof, which comprises binding sites that bind to a first specific epitope present on a ErbB1 receptor molecule, and (ii) a second package comprising a second antibody molecule which comprises binding sites that bind to a second different specific epitope on the same ErbB1 receptor molecule type.
20. A pharmaceutical kit according to claim 19, wherein at least said first or said second eptitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
21. A pharmaceutical kit according to claim 19, wherein said first and said second eptitope on the ErbB1 receptor is located within the ErbB1 receptor binding domain.
22. A pharmaceutical kit according to any of the claims 19 to 21, wherein at least one of said molecules binds to an epitope within the ErbB1 receptor binding domain to which the natural ligand of the receptor binds.
23. A pharmaceutical kit according to any of the claims 19 - 22, wherein said first antibody molecule is murine, chimeric or humanized monoclonal antibody 425, and said second molecule is murine, chimeric or humanized monoclonal antibody 225.
24. A pharmaceutical left according to claim 23 comprising a first package that comprises humanized MAb 425 (h425) and a second package that comprises chimeric MAb 225 (c225).
25. A pharmaceutical kit according to any of the claims 19 - 24 comprising additionally a third package comprising a cytotoxic agent.
26. A pharmaceutical kit according to claim 25, wherein said cytotoxic agent is a chemotherapeutic agent.
27. A pharmaceutical kit according to claim 26, wherein said chemotherapeutic agent is selected from any of the compounds of the group: cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, bleomycin.
28. A pharmaceutical kit according claim 26, wherein said cytotoxic drug is an ErbB
receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.
29. Use of a pharmaceutical composition or a pharmaceutical kit as defined in any of the claims 1 - 28, for the manufacture of a medicament to treat tumors or tumor related diseases.
CA2501818A 2002-10-10 2003-10-09 Pharmaceutical compositions directed to erb-b1 receptors Expired - Fee Related CA2501818C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02022390.5 2002-10-10
EP02022389 2002-10-10
EP02022389.7 2002-10-10
EP02022390 2002-10-10
PCT/EP2003/011164 WO2004032960A1 (en) 2002-10-10 2003-10-09 Pharmaceutical compositions directed to erb-b1 receptors

Publications (2)

Publication Number Publication Date
CA2501818A1 true CA2501818A1 (en) 2004-04-22
CA2501818C CA2501818C (en) 2012-03-27

Family

ID=32095025

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2501818A Expired - Fee Related CA2501818C (en) 2002-10-10 2003-10-09 Pharmaceutical compositions directed to erb-b1 receptors
CA2501821A Expired - Fee Related CA2501821C (en) 2002-10-10 2003-10-09 Bispecific anti-erb-b antibodies and their use in tumor therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2501821A Expired - Fee Related CA2501821C (en) 2002-10-10 2003-10-09 Bispecific anti-erb-b antibodies and their use in tumor therapy

Country Status (19)

Country Link
US (2) US7638125B2 (en)
EP (2) EP1549345A1 (en)
JP (3) JP2006505546A (en)
KR (2) KR20050057631A (en)
CN (1) CN1703243B (en)
AU (2) AU2003276084B2 (en)
BR (2) BR0315117A (en)
CA (2) CA2501818C (en)
CY (1) CY1116167T1 (en)
DK (1) DK1549344T3 (en)
ES (1) ES2533963T3 (en)
HK (2) HK1081449A1 (en)
HU (1) HUE025086T2 (en)
MX (2) MXPA05003795A (en)
PL (2) PL374586A1 (en)
PT (1) PT1549344E (en)
RU (2) RU2354402C2 (en)
SI (1) SI1549344T1 (en)
WO (2) WO2004032961A1 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
RU2294761C2 (en) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Method for treating resistant human tumors with epidermis growth factor receptors antagonists
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
SK9072003A3 (en) * 2001-01-09 2003-11-04 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DE60234094D1 (en) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd SPECIFIC TIE PROTEINS AND ITS USE
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PL374586A1 (en) * 2002-10-10 2005-10-31 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
AU2005224267B2 (en) * 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
WO2005118642A2 (en) 2004-06-01 2005-12-15 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
SI2298815T1 (en) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
EP1963370A1 (en) * 2005-12-06 2008-09-03 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
JP2009522316A (en) * 2006-01-04 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy using anti-EGFR antibody and anti-HER2 antibody
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
AU2007241130A1 (en) 2006-03-31 2007-11-01 EMD Serono Research Centre, Inc. Treatment of tumors expressing mutant EGF receptors
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
CN104013956B (en) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR
AU2013200209B9 (en) * 2007-03-01 2015-07-09 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
KR101676622B1 (en) * 2007-03-01 2016-11-17 심포젠 에이/에스 Recombinant anti-epidermal growth factor receptor antibody compositions
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
MX2010001757A (en) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof.
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
AU2008306202A1 (en) * 2007-10-02 2009-04-09 Merck Patent Gmbh Crystalline EGFR - matuzumab complex and matuzumab mimetics obtained thereof
WO2009070753A2 (en) * 2007-11-28 2009-06-04 The Scripps Research Institute Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CA2711256C (en) * 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
MX340204B (en) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof.
MX2011001927A (en) * 2008-08-29 2011-04-21 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions.
WO2010029534A1 (en) 2008-09-15 2010-03-18 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
MX2011009729A (en) 2009-03-20 2011-10-14 Genentech Inc Bispecific anti-her antibodies.
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
PL2417156T3 (en) * 2009-04-07 2015-07-31 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102712696A (en) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
ES2635313T3 (en) * 2009-10-14 2017-10-03 Acorda Therapeutics, Inc. Use of a neuregulin to treat a peripheral nerve injury
KR20120123299A (en) * 2009-12-04 2012-11-08 제넨테크, 인크. Multispecific antibodies, antibody analogs, compositions, and methods
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
CA2798273A1 (en) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
JP6082344B2 (en) 2010-05-27 2017-02-15 ゲンマブ エー／エス Monoclonal antibody against HER2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9464136B2 (en) * 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
RU2013110875A (en) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
ES2860748T3 (en) 2011-01-24 2021-10-05 Gilead Sciences Inc Selective Antibodies for EGFR-Presenting Cells with High Density
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
BR112013020338A2 (en) 2011-02-28 2016-10-18 Hoffmann La Roche monovalent antigen binding protein, pharmaceutical composition, use of monovalent antigen binding protein, method for treating a patient in need of therapy, method for preparing a monovalent antigen binding protein, nucleic acid, vector and cell hostess
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2710038B1 (en) 2011-05-16 2018-01-17 Yeda Research and Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
BR112014027291A2 (en) * 2012-05-02 2017-08-08 Symphogen As humanized pan-her antibody compositions
BR112014032193A2 (en) 2012-06-27 2017-06-27 Hoffmann La Roche bispecific antibody production and combination determination methods, bispecific antibody, formulation and use of bispecific antibody
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP2912062A1 (en) * 2012-10-24 2015-09-02 Yeda Research and Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
MX369276B (en) 2012-11-13 2019-11-04 Biontech Ag Agents for treatment of claudin expressing cancer diseases.
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
KR102089591B1 (en) 2013-07-29 2020-03-18 삼성전자주식회사 Anti-EGFR scFv fragment and Bispecific anti-c-Met/anti-EGFR antibodies comprising the same
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
EP3068892A4 (en) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
CN105980409B (en) 2013-11-27 2023-07-18 酵活生物制药有限公司 Bispecific antigen binding constructs targeting HER2
MA39599A (en) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage and administration anti-egfr therapeutics
WO2016070119A1 (en) * 2014-10-31 2016-05-06 Baylor College Of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
EP3223857A4 (en) * 2014-10-31 2018-06-27 Formation Biologics Inc. Egfr antibody-based combination therapy
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP6734919B2 (en) * 2015-10-02 2020-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Cell-based FRET assay for measuring simultaneous binding
LT3356411T (en) * 2015-10-02 2021-09-10 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
SG11201906313SA (en) * 2017-01-09 2019-08-27 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
CN110392692B (en) 2017-04-03 2023-07-21 豪夫迈·罗氏有限公司 Immunoconjugates of anti-PD-1 antibodies with mutant IL-2 or with IL-15
KR102408873B1 (en) 2017-04-05 2022-06-15 에프. 호프만-라 로슈 아게 Bispecific antibodies specifically binding to pd1 and lag3
TW202304994A (en) 2021-04-02 2023-02-01 美商泰尼歐生物公司 Agonistic anti-il-2r antibodies and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ATE247168T1 (en) * 1991-03-06 2003-08-15 Merck Patent Gmbh HUMANIZED MONOCLONAL ANTIBODIES
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH05320513A (en) * 1992-05-26 1993-12-03 Toray Dow Corning Silicone Co Ltd Clayey organopolysiloxane composition
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
EP1185559A2 (en) * 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
CA2409991A1 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
SK9072003A3 (en) 2001-01-09 2003-11-04 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1361893B1 (en) * 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
PL374586A1 (en) * 2002-10-10 2005-10-31 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy

Also Published As

Publication number Publication date
US7226592B2 (en) 2007-06-05
JP2006505545A (en) 2006-02-16
RU2354402C2 (en) 2009-05-10
BR0315123A (en) 2005-08-16
RU2005114482A (en) 2006-01-27
KR20050057631A (en) 2005-06-16
US7638125B2 (en) 2009-12-29
HK1081448A1 (en) 2006-05-19
US20060002920A1 (en) 2006-01-05
WO2004032961A1 (en) 2004-04-22
MXPA05003796A (en) 2006-02-22
AU2003273964A1 (en) 2004-05-04
CN1703243A (en) 2005-11-30
JP2010280727A (en) 2010-12-16
KR101088661B1 (en) 2011-12-01
ES2533963T3 (en) 2015-04-16
EP1549344B1 (en) 2015-01-07
CN1703243B (en) 2011-05-04
CA2501821A1 (en) 2004-04-22
PL374587A1 (en) 2005-10-31
CA2501821C (en) 2012-08-14
AU2003273964B2 (en) 2009-11-19
AU2003276084A1 (en) 2004-05-04
MXPA05003795A (en) 2005-06-08
EP1549344A1 (en) 2005-07-06
RU2005114480A (en) 2006-02-10
DK1549344T3 (en) 2015-04-07
BR0315117A (en) 2005-08-16
WO2004032960A1 (en) 2004-04-22
PL210545B1 (en) 2012-01-31
PL374586A1 (en) 2005-10-31
JP5179702B2 (en) 2013-04-10
HK1081449A1 (en) 2006-05-19
HUE025086T2 (en) 2016-02-29
JP2006505546A (en) 2006-02-16
CA2501818C (en) 2012-03-27
AU2003276084B2 (en) 2009-07-09
KR20050062612A (en) 2005-06-23
CY1116167T1 (en) 2017-02-08
EP1549345A1 (en) 2005-07-06
US20060165685A1 (en) 2006-07-27
PT1549344E (en) 2015-04-15
SI1549344T1 (en) 2015-05-29
RU2349340C2 (en) 2009-03-20

Similar Documents

Publication Publication Date Title
CA2501818A1 (en) Pharmaceutical compositions directed to erb-b1 receptors
JP2020063262A5 (en)
RU2335507C2 (en) Human monoclonal antibodies to receptor of epidermal growth factor (egfr), method of their preparation and usage, hybridome, transfectome, transgene animal, expression vector
Ludwig et al. Monoclonal antibody therapeutics and apoptosis
RU2018129962A (en) COMPOSITIONS OF ANTIBODIES TO ROR1 AND RELATED METHODS
JP2020501531A5 (en)
CA2436326A1 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
JP2018503380A5 (en)
JP2017512765A5 (en)
RU2003123781A (en) COMBINED THERAPY USING TYROSINKINASE RECEPTOR INHIBITORS AND ANGIOGENESIS INHIBITORS
JP2017527274A5 (en)
JP2017504577A5 (en)
WO1994004691A3 (en) Dimer and multimer forms of single chain polypeptides
RU2011111746A (en) COMPOSITIONS OF RECOMBINANT ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR
RU2013136172A (en) PROTEINS BINDING ANTIGEN GROWTH FACTOR, SIMILAR TO HEPARIN BINDING EPIDERMAL GROWTH FACTOR
RU2013125457A (en) COMBINATION ANTIBODIES AGAINST C-MET
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
RU2009114161A (en) ANTIBODIES AND FRAGMENTS OF HUMAN ANTIBODIES AGAINST THE ALPHA FOLAT RECEPTOR FOR RADIOIMMUNOTHERAPY OF OVARIAN CARCINOMA
JP2008515889A5 (en)
Spillner et al. Recombinant IgE antibody engineering to target EGFR
CA2356737A1 (en) Tumor necrosis factor antagonists and their use in endometriosis
Rockberg et al. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies
HRP20120975T1 (en) Therapeutic use of anti-cs1 antibodies
Mazor et al. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5 (Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts
WO2021084104A1 (en) Tetravalent antibody molecules

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20211012